The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study

The recruitment status of this study is unknown because the information has not been verified recently.

Verified March 2008 by McGill University Health Center.
Recruitment status was Recruiting

Sponsor:

Information provided by:

McGill University Health Center

ClinicalTrials.gov Identifier:

NCT00523653

First received: August 29, 2007

Last updated: March 17, 2008

Last verified: March 2008

History of Changes

Purpose

Dilated cardiomyopathy (DCM) affects about 200,000 Canadians. Eighty percent of these cases are of unclear cause, often occuring in families. We believe that mutations in specific already-identified genes contribute to DCM in Quebec and that certain mutations may account for a significant proportion of cases due to the well-documented "founder effect". Two hundred patients with DCM followed in our Heart Function Clinic will be approached for one blood sample at their routine clinic visit to test this hypothesis. The samples will be tested in the Laboratory of Cardiovascular Genetics at the Royal Victoria Hospital.

Condition	Intervention
Dilated Cardiomyopathy (DCM)	Other: blood test


Study Type:	Observational
Study Design:	Observational Model: Family-Based Time Perspective: Prospective

Resource links provided by NLM:

Genetics Home Reference related topics: DMD-associated dilated cardiomyopathy familial dilated cardiomyopathy

MedlinePlus related topics: Cardiomyopathy

Genetic and Rare Diseases Information Center resources: Dilated Cardiomyopathy

U.S. FDA Resources

Further study details as provided by McGill University Health Center:


Estimated Enrollment:	200
Study Start Date:	January 2008
Estimated Study Completion Date:	December 2008

Intervention Details:

looking at DNA

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Patients with Dilated cardiomyopathy followed at the Heart Function Clinic and their families

Criteria

Inclusion Criteria:

Followed at MUHC Heart Function Centre
Documented EF of less than or equal to 35% and an enlarged heart with a left ventricular end-diastolic size of greater than 6 cm.
Patient's written consent

Exclusion Criteria:

Patients with a known underlying condition that results in a weakened and enlarged heart
Patients unable to read and understand the consent form
Patients who do not wish to participate

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00523653

Contacts


Contact: Nadia S Giannetti, MD	(514)934 1934 ext 32850	nadia.giannetti@much.mcgill.ca

Locations


Canada, Quebec
Royal Victoria Hospital	Recruiting
Montreal, Quebec, Canada, H3A 1A1
Contact: Nadia Giannetti, MD nadia.giannetti@muhc.mcgill.ca

Sponsors and Collaborators

McGill University Health Center

Investigators


Principal Investigator:	Nadia S Giannetti, MD	McGill University Hospital Centre
Principal Investigator:	Jamie Engert, PhD	McGill University Health Center

More Information


Responsible Party:	Dr Nadia Giannetti, McGill University Health Center
ClinicalTrials.gov Identifier:	NCT00523653 History of Changes
Other Study ID Numbers:	BMB 07-004
Study First Received:	August 29, 2007
Last Updated:	March 17, 2008
Health Authority:	Canada: Ethics Review Committee

Additional relevant MeSH terms:


Cardiomyopathies Cardiomyopathy, Dilated Heart Diseases Cardiovascular Diseases Cardiomegaly

ClinicalTrials.gov processed this record on September 23, 2016

To Top